CTOs on the Move

Mitsubishi Tanabe Pharma Development America

www.m-pharma.com

 
Mitsubishi Tanabe Pharma Development America is a Warren, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.m-pharma.com
  • 25 Independence Blvd Ste 201
    Warren, NJ USA 07059
  • Phone: 908.607.1950

Executives

Name Title Contact Details

Similar Companies

M Silicon Biosystems

Solutions for isolation, recovery, and analysis of intact, individual rare cells. Single "cell sorter"

Kurome Therapeutics

Kurome Therapeutics is developing therapies that target cancer cells that have co-opted immune signaling pathways in order to avoid destruction by traditional therapeutic agents and subvert adaptive resistance mechanisms.

Novome Biotechnologies

Novome Biotechnologies is engineering bacteria from the human gut to treat diseases. Based on pioneering technology developed at Stanford University, we bring together experts in the fields of synthetic biology and the microbiome to build novel cell-based therapies.

Rubius Therapeutics

Rubius Therapeutics is a biopharmaceutical company pioneering a new era of cellular medicines. Our proprietary RED PLATFORM™ was designed to genetically engineer and culture Red Cell Therapeutics™ that are selective, potent and ready to-use cellular therapies for the potential treatment of several diseases across multiple therapeutic areas. Our initial focus is to advance RCT™ product candidates for the treatment cancer and autoimmune diseases by leveraging two distinct therapeutic modalities — potent cell-cell interaction and tolerance induction. We are currently enrolling patients in a Phase 1/2 clinical trial of RTX-240; the trial has two Phase 1 arms enrolling adult patients with advanced solid tumors: an ongoing monotherapy dose escalation arm in adults with relapsed/refractory or locally advanced solid tumors and a combination therapy dose escalation arm with pembrolizumab in adults with relapsed/refractory or locally advanced solid tumors. In April 2022, the combination arm with pembrolizumab was expanded to focus on non-small cell lung cancer and renal cell carcinoma patients. We are also enrolling patients in a Phase 1/2 clinical trial of RTX-224 for the treatment of patients with certain advanced solid tumors, including non-small cell lung cancer, cutaneous melanoma, head and neck squamous cell carcinoma, urothelial (bladder) carcinoma and triple-negative breast cancer.

IQuum

IQuum is a Marlborough, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.